BL&H acquires Trisenox licence for South Korea
This article was originally published in Scrip
Executive Summary
Nippon Shinyaku has sublicensed Cephalon's arsenic trioxide product Trisenox to BL&H for development and marketing in South Korea. The therapy, to which the Japanese firm acquired exclusive marketing rights in Japan, South Korea and Taiwan in late 2002, will be developed by BL&H for relapsed or refractory acute promyelocytic leukaemia (APL), its main indication. The disease affects around 250 people a year in South Korea, noted Nippon Shinyaku, which will receive undisclosed development milestones as part of the deal. Trisenox was launched for APL in Japan around four years ago.